Check out your Company Bowl for anonymous work chats.
Grifols today has received FDA approval for its Procleix Panther System featuring Automation Ready Technology (ART) for use with the following U.S.-licensed products: Procleix Ultrio Elite Assay, Procleix West Nile Virus Assay, Procleix Zika Virus Assay and the Procleix Babesia Assay. ART technology features significant hardware and software improvements that support blood-banking operations of all sizes, such as instrument networkability and information sharing. The Procleix Panther System featuring ART has been available since October 2019 in all markets accepting the CE mark.
Grifols today announced it has begun the collection of convalescent plasma in the U.S. The company is selecting volunteer donors who have recovered from COVID-19 to donate their plasma to produce a hyperimmune globulin that, if proven effective, could be a viable treatment for COVID-19. Potential donors can call 866-END-CV19 to learn more about where they can donate. Please see the press release for more information.
Grifols will partner with the FDA and other U.S. public health agencies to collect convalescent plasma from recovered COVID-19 patients. The company will produce hyperimmune globulin from this plasma and will collaborate with the public health agencies on the necessary preclinical and clinical studies to determine the treatment efficacy. http://adtrk.tw/tp/rj6.z9HV_y-K
Grifols delivered strong results in 2019, reporting revenues of 5.1 billion euros, a 13.6% increase over the previous year. The EBITDA increased 17.3% to 1.4 billion euros and profits grew to 625 million euros. Grifols’ long-term sustainable growth strategy continued to deliver solid results across all divisions and regions.
Grifols today announced that the European Commission has approved U.S.-based Rigel Pharmaceuticals' TAVLESSE® (fostamatinib) for the treatment of chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments. In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. The launch of TAVLESSE® in Europe and Turkey, where Grifols has exclusive rights, reinforces Grifols’ commercial strategy and reflects the company’s commitment to continue expanding its product portfolio to benefit patients. For more information:
2019 has been a year of great achievements for Grifols. As we turned 110 years old, we launched new solutions to provide better treatment options for our patients, presented promising AMBAR results that show the potential of plasma proteins to treat high-prevalence diseases, and once again received recognition for the industrial excellence of our state-of-the-art facilities. We begin another year as committed as ever to our mission: continuing to help thousands of people around the world. Our horizons keep expanding with our pioneering spirit leading the way. Our best wishes for the New Year!
Grifols today reinforced its leadership in treating diseases with immunoglobulins (IG) as it launched Xembify®, the company’s first 20% subcutaneous immunoglobulin therapy for the treatment of patients with primary immunodeficiency (PI). With Xembify, the company continues to expand its industry-leading portfolio of plasma-derived medicines to enhance the health and well-being of patients around the world.
Grifols today at the CTAD conference in San Diego released new and complete data from its breakthrough clinical trial on Alzheimer’s disease, AMBAR, strengthening previous results that show a reduction in the progression of the disease in patients with mild-to-moderate Alzheimer’s. New neuroimaging data show less neuronal damage in patients receiving the plasma proteins albumin and immunoglobulin, the mainstays of the AMBAR protocol. Grifols also announced another clinical trial in 2020, AMBAR II, to complement the just-completed study.
Grifols expands in Latin America with the start of production of its new blood-collection systems plant in Campo Largo, Brazil. With an annual capacity in excess of 10 million blood collection bags, the more than 5,500-square-meter plant is expected to gradually increase output to serve the broader Latin American region. http://glassdoor.com/slink.htm?key=vMHJh
Grifols continued to deliver strong financial results in 2019, reporting 3.7 billion in revenues for the first nine months of the year. The company delivered solid performance across all its business divisions. Please see full results here: http://glassdoor.com/slink.htm?key=vMHXw
